Purpose <p>To evaluate the temporal evolution of the modified Cekirge–Saatci classification (mCSC) after flow diverter (FD) treatment and to investigate its predictive value for recanalization using an exploratory mCSC-based risk stratification approach.</p> Methods <p>This retrospective study included 50 patients with intracranial aneurysms treated with FD between 2015 and 2026. Patients were stratified into no-risk, intermediate-risk, and high-risk levels based on mCSC classes at 4- and 12-month angiographic follow-up. Clinical, morphological, and treatment-related variables were analyzed. The association between mCSC risk levels and recanalization was assessed using univariate and multivariate logistic regression analyses.</p> Results <p>The mean age was 55.2 ± 12.9 years, and 70% of patients were female. Recanalization occurred in 28% of cases during a mean follow-up of 104.8 ± 24.4 months. In univariate analysis, hypertension (71.4% vs. 36.1%, <i>p</i> = 0.024) and aneurysm size (median 5.5&#xa0;mm vs. 3.5&#xa0;mm, <i>p</i> = 0.036) were associated with recanalization. Both 4-month and 12-month mCSC risk levels were significantly correlated with recanalization (<i>p</i> = 0.015 and <i>p</i> = 0.014, respectively). In multivariate analysis, the 12-month mCSC risk level remained associated with recanalization within the exploratory multivariable model, with higher-risk categories demonstrating increased odds of recanalization (OR: 31.031, <i>p</i> = 0.015). Temporal analysis demonstrated dynamic transitions between risk categories, with a subset of patients progressing from no to high risk over time.</p> Conclusion <p>The mCSC should be considered a dynamic rather than a static classification system. A risk-based interpretation and longitudinal evaluation of mCSC may provide prognostic information regarding recanalization and may assist future development of individualized follow-up strategies after FD treatment.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Dynamic risk stratification using the modified Cekirge–Saatci classification (mCSC) predicts recanalization after flow diversion

  • Hüseyin Akkaya,
  • Nargız Amiraslanova,
  • Fatih Uzunkaya,
  • Ayşegül İdil Soylu

摘要

Purpose

To evaluate the temporal evolution of the modified Cekirge–Saatci classification (mCSC) after flow diverter (FD) treatment and to investigate its predictive value for recanalization using an exploratory mCSC-based risk stratification approach.

Methods

This retrospective study included 50 patients with intracranial aneurysms treated with FD between 2015 and 2026. Patients were stratified into no-risk, intermediate-risk, and high-risk levels based on mCSC classes at 4- and 12-month angiographic follow-up. Clinical, morphological, and treatment-related variables were analyzed. The association between mCSC risk levels and recanalization was assessed using univariate and multivariate logistic regression analyses.

Results

The mean age was 55.2 ± 12.9 years, and 70% of patients were female. Recanalization occurred in 28% of cases during a mean follow-up of 104.8 ± 24.4 months. In univariate analysis, hypertension (71.4% vs. 36.1%, p = 0.024) and aneurysm size (median 5.5 mm vs. 3.5 mm, p = 0.036) were associated with recanalization. Both 4-month and 12-month mCSC risk levels were significantly correlated with recanalization (p = 0.015 and p = 0.014, respectively). In multivariate analysis, the 12-month mCSC risk level remained associated with recanalization within the exploratory multivariable model, with higher-risk categories demonstrating increased odds of recanalization (OR: 31.031, p = 0.015). Temporal analysis demonstrated dynamic transitions between risk categories, with a subset of patients progressing from no to high risk over time.

Conclusion

The mCSC should be considered a dynamic rather than a static classification system. A risk-based interpretation and longitudinal evaluation of mCSC may provide prognostic information regarding recanalization and may assist future development of individualized follow-up strategies after FD treatment.